Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 315-319

  Peña, Rocio ^a   Marquina, David ^a   Serrano, Ana ^a   elFakih, Yamily ^a   de Baptista, Enma Araujo ^b   Carrizo, Edgardo ^c   Fernández, Virginia ^c   Valery, Lenin ^b   Teneud, Luis ^a   Baptista, Trino ^a  

^a Universidad De Los Andes Facultad de Medicina   (Venezuela)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

^c UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Anthropometric variables; Atypical antipsychotics; Drug free subjects; Leptin; Metabolic dysfunction; Obesity

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; LEPTIN; LEPTIN RECEPTOR; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ALLELE; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENDER; GENETIC POLYMORPHISM; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BODY MASS INDEX; BODY WEIGHT; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MENTAL DISORDERS; MIDDLE AGED; OUTLIERS, DRG; RECEPTORS, LEPTIN; SCHIZOPHRENIA; SEX FACTORS; WEIGHT GAIN;

EID: 56249095439     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.08.031     Document Type: Article

References (22)

1. Baptista T., Sandia I., LaCruz A., Rangel N., de Mendoza S., Beaulieu S., Contreras Q., Galeazzi T., and Vargas D. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int. Clin. Psychopharmacol. 22 2 (2007) 69-76
2. Baptista T., Dávila A., ElFakih Y., Uzcátegui E., Rangel N., Olivares Y., Galeazzi T., Vargas D., Peña R., Marquina D., Villarroel V., Teneud L., and Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and body mass index before and after olanzapine treatment in schizophrenia. Int. Clin. Psychopharmacol. 22 4 (2007) 205-211
3. Baptista, T., Serrano, A., ElFakih, Y., Uzcátegui, E., Uzcátegui, M., in preparation. Prevalence of the metabolic syndrome during tretment with first and second generation antipsychotic drugs in Venezuela.
4. British Medical Association & Royal Pharmaceutical Society. British National Formulary. 1994; London & Wallingford: British Medical Journal & Pharmaceutical Press.
5. Coll A.P., Farooqi I.S., and O'Rahilly S. The hormonal control of food intake. Cell 129 2 (2007) 251-262
6. Cooper G.D., Pickvance L.C., Wilding J.P., Halford J.C., and Goudie A.J. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacol. (Berl) 181 1 (2005) 80-89
7. De Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. J. Clin. Psychopharmacol. 28 2 (2008) 125-131
8. Haupt D.W., and Newcomer J. Plasma leptin and antipsychotic-induced body weight gain. Neuropsychopharmacol. 30 12 (2005) 1770-1771
9. Haupt D.W., Luber A., Maeda J., Melson A.K., Schweiger J.A., and Newcomer J.W. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacol. 30 1 (2005) 184-191
10. Jin H., Meyer J.M., Mudaliar S., and Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin and adiponectin. Schizophr. Res. 100 1-3 (2008) 70-85
11. Kang S.G., Lee H.J., Park Y.M., Choi J.E., Han C., Kim Y.K., Kim S.H., Lee M.S., Joe S.H., Jung I.K., and Kim L. Possible association between the - 2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 1 (2008) 160-163
12. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Emsberger P., Jayathilakek K., Meltzer H.Y., and Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol. 28 3 (2003) 519-526
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
14. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 61 10 (2000) 742-749
15. Monteleone P., Fabrazzo M., Tortorella A., LaPia S., and Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J. Clin. Psychopharmacol. 22 4 (2002) 424-426
16. Newcomer J. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1 (2007) 20-27
17. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gómez-Reino J.J., and Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579 2 (2005) 295-301
18. Ozdemir V., Williams-Jones B., Cooper D.M., Someya T., and Godard B. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 8 2 (2007) 177-185
19. Wannamethee S.G., Tchernova J., Whincup P., Lowe G.D., Kelly A., Rumley A., Wallace A.M., and Sattar N. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 191 2 (2007) 418-426
20. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64 6 (2003) 663-667
21. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Cao L.Y., Xu Q., Shen Y., Kosten T.A., and Kosten T.R. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J. Clin. Psychopharmacol. 27 3 (2007) 246-251
22. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pöllmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 37 3 (2003) 193-220